 Shaoxing jinlu Biotechnology Co. LTD. was established in May 2013 with an investment of 12 million yuan, with 2,000 square meters of office space and production facilities, It includes research and development laboratories, quality inspection rooms, 400 square meters of clean workshops, 1 million square meters of clean workshops, stand-alone office areas, finished room, raw materials warehouse, chemical warehouse, semi-finished goods warehouse, finished goods warehouse (including cold storage) and water making room.It includes the assistant facilities of R&D laboratory, quality inspection room, 400 square meters of clean workshop, 100 square meters of clean workshop. Shaoxing Ruizheng Biotech Co. LTD. is a 330 Bio-Diagnostic Reagent Industry Accelerator, Incubation Base, Industrialization Base and High-Level Talent Innovation Start-up Base in Shaoxing. Help enterprises to shorten the time of new product development, reduce the cost of development and the start-up threshold of overseas teams, increase the success rate of projects, attract more overseas projects and talents to settle in Shaoxing. To reduce the technological threshold of biological diagnostic reagents development, attract traditional enterprises to enter new products, realize strategic transformation, cultivate a number of bio-diagnostic enterprises with independent innovation ability, and promote the rapid development of Shaoxing biological diagnostic industry. 
Stephan W. Morris, MD （Clinical oncologist researcher entrepreneur） American InsightGenetics and HealthChart LLC company promoter, who was presided over by a number of ALK gene related patent ALK gene normal function and the pathogenic mechanism and clinical application research of the blazers and academic leaders, and has obtained the ALK gene patent for invention, the U.S. national institutes of health and the American cancer society provides a number of research fund gainer, now shaoxing jinlu science adviser. Beijing Biolancet Technology Co. LTD Shaoxing Ruichuang Biotechnology Co. LTD USA Insight Genetics USA HealthChart LLC USA City Of Hopemedical center USA Apo Cell Co Leica Biosystems Partners Company formation in February 2015 In February 2016 to complete the clean plant, cold storage, water system construction In-Situ Hybridization Sample Pretreatment Reagents Were Filed and Sold in August 2016 R&D and customization of various probes using fluorescence in situ hybridization as a technology platform started in June 2016
Completion of the quality management system document in June 2016 Completion of In-Situ Hybridization Sample Pretreatment Reagents Class I and Formal Sale in August 2016 Completion of small, pilot and trial HER2 gene test kit in December 2016 Completion of Registration Test for HER2 Gene Test Kit in May 2017 Development of a ALK gene test kit in September 2017 The development of more than 50 probes, including ph-like, BCR/ABL, was completed in November 2017 Clinical trial of the HER2 gene test kit started in June 2018 |
